HBIO Quote, Financials, Valuation and Earnings

Azenta has a net margin of 0.07% compared to Harvard Bioscience's net margin of -9.04%. Harvard Bioscience's return on equity of -18.36% beat Azenta's return on equity of -7.97%.

Harvard Bioscience has a consensus price target of $4.50, signalling upside risk potential of 1093.95%. On the other hand Azenta has an analysts' consensus of $51.60 which suggests that it could grow by 93.04%. Given that Harvard Bioscience has higher upside potential than Azenta, analysts believe Harvard Bioscience is more attractive than Azenta.

Harvard Bioscience has a beta of 1.468, which suggesting that the stock is 46.794% more volatile than S&P 500. In comparison Azenta has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.003%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Harvard Bioscience quarterly revenues are $24.6M, which are smaller than Azenta quarterly revenues of $147.5M. Harvard Bioscience's net income of $18K is higher than Azenta's net income of -$13.3M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.17x versus 2.08x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of 0.07% compared to Harvard Bioscience's net margin of -728.57%. Harvard Bioscience's return on equity of -18.36% beat Bionano Genomics's return on equity of -158.95%.

Harvard Bioscience has a consensus price target of $4.50, signalling upside risk potential of 1093.95%. On the other hand Bionano Genomics has an analysts' consensus of $7.00 which suggests that it could grow by 62.79%. Given that Harvard Bioscience has higher upside potential than Bionano Genomics, analysts believe Harvard Bioscience is more attractive than Bionano Genomics.

Harvard Bioscience has a beta of 1.468, which suggesting that the stock is 46.794% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.086, suggesting its more volatile than the S&P 500 by 108.641%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Harvard Bioscience quarterly revenues are $24.6M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Harvard Bioscience's net income of $18K is higher than Bionano Genomics's net income of -$44.2M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.17x versus 0.10x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 0.07% compared to Harvard Bioscience's net margin of 1.4%. Harvard Bioscience's return on equity of -18.36% beat Bruker's return on equity of 6.78%.

Harvard Bioscience has a consensus price target of $4.50, signalling upside risk potential of 1093.95%. On the other hand Bruker has an analysts' consensus of $60.13 which suggests that it could grow by 53.9%. Given that Harvard Bioscience has higher upside potential than Bruker, analysts believe Harvard Bioscience is more attractive than Bruker.

Harvard Bioscience has a beta of 1.468, which suggesting that the stock is 46.794% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.51% to investors and pays a quarterly dividend of $0.05 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Harvard Bioscience quarterly revenues are $24.6M, which are smaller than Bruker quarterly revenues of $979.6M. Harvard Bioscience's net income of $18K is lower than Bruker's net income of $13.7M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bruker's PE ratio is 51.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.17x versus 1.73x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies has a net margin of 0.07% compared to Harvard Bioscience's net margin of --. Harvard Bioscience's return on equity of -18.36% beat Kestra Medical Technologies's return on equity of --.

Harvard Bioscience has a consensus price target of $4.50, signalling upside risk potential of 1093.95%. On the other hand Kestra Medical Technologies has an analysts' consensus of $27.50 which suggests that it could grow by 13.45%. Given that Harvard Bioscience has higher upside potential than Kestra Medical Technologies, analysts believe Harvard Bioscience is more attractive than Kestra Medical Technologies.

Harvard Bioscience has a beta of 1.468, which suggesting that the stock is 46.794% more volatile than S&P 500. In comparison Kestra Medical Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Kestra Medical Technologies pays out -1.99% of its earnings as a dividend.

Harvard Bioscience quarterly revenues are $24.6M, which are larger than Kestra Medical Technologies quarterly revenues of --. Harvard Bioscience's net income of $18K is higher than Kestra Medical Technologies's net income of --. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Kestra Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.17x versus 24.23x for Kestra Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.